Patents by Inventor Benoit Derijard

Benoit Derijard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Optical Disc Apparatus
    Publication number: 20090053231
    Abstract: Disclosed are human mitogen-activated (MAP) kinase kinase isoforms (MKKs). MKKs mediate unique signal transduction pathways that activate human MAP kinases p38 and JNK, which result in activation of other factors, including activating transcription factor-2 (ATF2) and c-Jun. The pathways are activated by a number of factors, including cytokines and environmental stress. Methods are provided for identifying reagents that modulate MKK function or activity and for the use of such reagents in the treatment of MKK-mediated disorders.
    Type: Application
    Filed: June 18, 2008
    Publication date: February 26, 2009
    Inventors: Roger J. Davis, Joel Raingeaud, Benoit Derijard
  • Oncoprotein protein kinase
    Publication number: 20070077581
    Abstract: An isolated polypeptide (JNK) characterized by having a molecular weight of 46 kD as determined by reducing SDS-PAGE, having serine and Threonine kinase activity, phosphorylating the c-Jun N-terminal activation domain and polynucleotide sequences and method of deterction of JNK are provided herein. JNK phosphorylates c-Jun N-terminal activation domain which affects gene expression from AP-1 sites.
    Type: Application
    Filed: September 15, 2006
    Publication date: April 5, 2007
    Inventors: Michael Karin, Masahiko Hibi, Anning Lin, Roger Davis, Benoit Derijard
  • Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
    Publication number: 20050272077
    Abstract: Disclosed are human mitogen-activated (MAP) kinase kinase isoforms (MKKs). MKKs mediate unique signal transduction pathways that activate human MAP kinases p38 and JNK, which result in activation of other factors, including activating transcription factor-2 (ATF2) and c-Jun. The pathways are activated by a number of factors, including cytokines and environmental stress. Methods are provided for identifying reagents that modulate MKK function or activity and for the use of such reagents in the treatment of MKK-mediated disorders.
    Type: Application
    Filed: April 21, 2005
    Publication date: December 8, 2005
    Inventors: Roger Davis, Joel Raingeaud, Benoit Derijard
  • Oncoprotein protein kinase
    Patent number: 6863888
    Abstract: An isolated polypeptide (JNK) characterized by having a molecular weight of 46 kD as determined by reducing SDS-PAGE, having serine and threonine kinase activity, phosphorylating the c-Jun N-terminal activation domain and polynucleotide sequences and method of detection of JNK are provided herein. JNK phosphorylates c-Jun N-terminal activation domain which affects gene expression from AP-1 sites.
    Type: Grant
    Filed: May 18, 2001
    Date of Patent: March 8, 2005
    Assignee: The Regents of the University of California
    Inventors: Michael Karin, Masahiko Hibi, Anning Lin, Roger Davis, Benoit Derijard
  • Oncoprotein protein kinase
    Patent number: 6846644
    Abstract: An isolated polypeptide (JNK) characterized by having a molecular weight of 46 kD as determined by reducing SDS-PAGE, having serine and threonine kinase activity, phosphorylating the c-Jun N-terminal activation domain and polynucleotide sequences and method of detection of JNK are provided herein. JNK phosphorylates c-Jun N-terminal activation domain which affects gene expression from AP-1 sites.
    Type: Grant
    Filed: May 18, 2001
    Date of Patent: January 25, 2005
    Assignee: The Regents of the University of California
    Inventors: Roger Davis, Benoit Derijard, Michael Karin, Masahiko Hibi, Anning Lin
  • Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
    Patent number: 6541605
    Abstract: Disclosed are human mitogen-activated (MAP) kinase kinase isoforms (MKKs). MKKs mediate unique signal transduction pathways that activate human MAP kinases p38 and JNK, which result in activation of other factors, including activating transcription factor-2 (ATF2) and c-Jun. The pathways are activated by a number of factors, including cytokines and environmental stress. Methods are provided for identifying reagents that modulate MKK function or activity and for the use of such reagents in the treatment of MKK-mediated disorders.
    Type: Grant
    Filed: April 7, 1998
    Date of Patent: April 1, 2003
    Assignee: University of Massachusetts
    Inventors: Roger J. Davis, Joel Raingeaud, Benoit Derijard
  • Oncoprotein protein kinase
    Patent number: 6514745
    Abstract: An isolated polypeptide (JNK) characterized by having a molecular weight of 46kD as determined by reducing SDS-PAGE, having serine and threonine kinase activity, phosphorylating the c-Jun N-terminal activation domain and polynucleotide sequences and method of detection of JNK are provided herein. JNK phosphorylates c-Jun N-terminal activation domain which affects gene expression from AP-1 sites.
    Type: Grant
    Filed: March 25, 1994
    Date of Patent: February 4, 2003
    Assignee: The Regents of the University of California
    Inventors: Michael Karin, Masahiko Hibi, Anning Lin, Roger Davis, Benoit Derijard
  • Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
    Publication number: 20020102691
    Abstract: Disclosed are human mitogen-activated (MAP) kinase kinase isoforms (MKKs). MKKs mediate unique signal transduction pathways that activate human MAP kinases p38 and JNK, which result in activation of other factors, including activating transcription factor-2 (ATF2) and c-Jun. The pathways are activated by a number of factors, including cytokines and environmental stress. Methods are provided for identifying reagents that modulate MKK function or activity and for the use of such reagents in the treatment of MKK-mediated disorders.
    Type: Application
    Filed: January 16, 2001
    Publication date: August 1, 2002
    Applicant: University of Massachusetts, a Massachusetts corporation
    Inventors: Roger J. Davis, Joel Raingeaud, Benoit Derijard
  • Cytokine-stress- and oncoprotein-activated human protein kinase kinases
    Patent number: 6174676
    Abstract: Disclosed are human mitogen-activated (MAP) kinase kinase isoforms (MKKs). MKKs mediate unique signal transduction pathways that activate human-MAP kinases p38 and JNK, which result in activation of other factors, including activating transcription factor-2 (ATF2) and c-Jun. The pathways are activated by a number of factors, including cytokines and environmental stress. Methods are provided for identifying reagents that modulate MKK function or activity and for the use of such reagents in the treatment of MKK-mediated disorders.
    Type: Grant
    Filed: September 8, 1998
    Date of Patent: January 16, 2001
    Assignee: University of Massachusetts
    Inventors: Roger J. Davis, Joel Raingeaud, Benoit Derijard
  • Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
    Patent number: 5804427
    Abstract: Disclosed are human mitogen-activated (MAP) kinase kinase isoforms (MKKs). MKKs mediate unique signal transduction pathways that activate human MAP kinases p38 and JNK, which result in activation of other factors, including activating transcription factor-2 (ATF2) and c-Jun. The pathways are activated by a number of factors, including cytokines and environmental stress. Methods are provided for identifying reagents that modulate MKK function or activity and for the use of such reagents in the treatment of MKK-mediated disorders.
    Type: Grant
    Filed: May 19, 1995
    Date of Patent: September 8, 1998
    Assignee: University of Massachusetts
    Inventors: Roger Davis, Joel Raingeaud, Benoit Derijard
  • Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
    Patent number: 5736381
    Abstract: Disclosed are human mitogen-activated (MAP) kinase kinase isoforms (MKKs). MKKs mediate unique signal transduction pathways that activate human MAP kinases p38 and JNK, which result in activation of other factors, including activating transcription factor-2 (ATF2) and c-Jun. The pathways are activated by a number of factors, including cytokines and environmental stress. Methods are provided for identifying reagents that modulate MKK function or activity and for the use of such reagents in the treatment of MKK-mediated disorders.
    Type: Grant
    Filed: September 19, 1995
    Date of Patent: April 7, 1998
    Inventors: Roger J. Davis, Shashi Gupta, Joel Raingeaud, Benoit Derijard